Acrivon Therapeutics (ACRV) Stock Chart & Stock Price History → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free ACRV Stock Alerts $8.77 +0.63 (+7.74%) (As of 05/10/2024 ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Acrivon Therapeutics Stock Price Performance5 Day Performance-0.68%1 Month Performance-5.60%3 Month Performance+141.60%6 Month Performance+100.46%Year-To-Date Performance+78.25%1 Year Performance-35.47% Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. ACRV Stock Chart for Saturday, May, 11, 2024 ACRV Chart by TradingView Acrivon Therapeutics Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/10/2024$8.14$8.77+7.74%$8.78$7.98100,179 shs$198.53 million05/09/2024$8.23$8.14-1.09%$8.74$8.00227,365 shs$184.27 million05/08/2024$8.34$8.23-1.32%$8.36$8.02128,113 shs$186.30 million05/07/2024$8.83$8.34-5.55%$8.74$8.20175,933 shs$188.82 million05/06/2024$9.59$8.83-7.92%$9.58$8.60146,917 shs$199.91 million05/03/2024$8.46$9.59+13.36%$10.29$8.31375,244 shs$217.12 million Get the Latest News and Ratings for ACRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/02/2024$8.23$8.46+2.79%$8.89$8.10192,819 shs$186.30 million05/01/2024$9.09$8.23-9.46%$9.36$8.09259,115 shs$186.33 million04/30/2024$10.00$9.09-9.10%$9.97$9.00130,075 shs$205.80 million04/29/2024$8.46$10.00+18.20%$10.16$8.18239,144 shs$226.40 million04/26/2024$8.47$8.46-0.12%$8.78$8.20276,263 shs$191.53 million04/25/2024$9.50$8.47-10.84%$10.12$7.80695,095 shs$191.76 million04/24/2024$9.82$9.50-3.26%$9.87$9.09310,539 shs$215.08 million04/23/2024$9.51$9.82+3.26%$10.27$9.25320,561 shs$222.30 million04/22/2024$9.39$9.51+1.28%$9.98$9.08311,449 shs$215.31 million04/19/2024$10.54$9.39-10.91%$10.77$9.11627,504 shs$212.59 million04/18/2024$10.34$10.54+1.93%$11.50$10.01369,882 shs$238.63 million04/17/2024$9.47$10.34+9.19%$10.49$9.38288,275 shs$234.10 million04/16/2024$9.61$9.47-1.46%$9.80$9.15202,368 shs$214.40 million04/15/2024$9.99$9.61-3.80%$10.60$9.15394,205 shs$217.57 million04/12/2024$9.29$9.99+7.53%$10.36$9.21345,386 shs$226.17 million04/11/2024$10.39$9.29-10.59%$10.30$9.20488,524 shs$210.33 million04/10/2024$9.62$10.39+8.00%$10.48$9.091.05 million shs$235.23 million04/09/2024$5.91$9.62+62.77%$11.90$8.8038.26 million shs$217.77 million04/08/2024$6.48$5.91-8.80%$6.63$5.7069,199 shs$133.80 million04/05/2024$6.69$6.48-3.14%$6.65$6.2521,925 shs$146.71 million04/04/2024$6.66$6.69+0.45%$6.97$6.5232,796 shs$151.44 million04/03/2024$6.69$6.66-0.45%$6.80$6.0233,538 shs$150.78 million04/02/2024$7.25$6.69-7.72%$7.24$6.5052,526 shs$148.45 million04/01/2024$7.15$7.25+1.40%$7.70$6.8186,436 shs$160.88 million03/29/2024$7.15$7.15$7.31$6.01127,903 shs$158.69 million03/28/2024$6.47$7.15+10.60%$7.30$6.01127,890 shs$158.66 million03/27/2024$6.33$6.47+2.13%$6.56$6.0027,623 shs$143.46 million03/26/2024$6.25$6.33+1.28%$6.91$6.2045,994 shs$140.46 million03/25/2024$6.19$6.25+0.97%$6.63$6.1143,603 shs$138.69 million03/22/2024$6.33$6.19-2.21%$6.36$5.7545,884 shs$137.36 million03/21/2024$6.29$6.33+0.64%$6.90$6.1668,515 shs$140.46 million03/20/2024$5.47$6.29+14.99%$6.66$5.50115,843 shs$139.58 million03/19/2024$5.65$5.47-3.19%$5.74$5.1268,427 shs$121.38 million03/18/2024$6.19$5.65-8.72%$6.64$5.5785,594 shs$125.37 millionCollapse of the Petrodollar (Ad)The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.In answer to this issue, we have released a Special Report to the public.03/15/2024$5.07$6.19+22.09%$6.80$5.03465,835 shs$137.36 million03/14/2024$5.28$5.07-3.98%$5.46$5.0232,237 shs$112.50 million03/13/2024$4.99$5.28+5.81%$5.31$4.9919,342 shs$117.16 million03/12/2024$4.95$4.99+0.81%$5.20$4.8829,585 shs$110.73 million03/11/2024$4.95$4.95$5.34$4.49158,439 shs$109.84 million03/08/2024$5.13$4.95-3.51%$5.50$4.8542,218 shs$109.84 million03/07/2024$4.75$5.13+8.00%$5.30$4.7053,951 shs$113.84 million03/06/2024$4.94$4.75-3.85%$5.35$4.6553,351 shs$105.40 million03/05/2024$5.05$4.94-2.18%$5.22$4.6558,421 shs$109.64 million03/04/2024$5.70$5.05-11.40%$5.92$5.04124,561 shs$112.06 million03/01/2024$4.86$5.70+17.28%$5.94$5.21169,493 shs$126.48 million02/29/2024$4.47$4.86+8.72%$5.13$4.3160,015 shs$107.84 million02/28/2024$5.20$4.47-14.04%$5.31$4.4047,078 shs$99.19 million02/27/2024$4.26$5.20+22.07%$5.46$4.26149,672 shs$115.39 million02/26/2024$3.89$4.26+9.51%$4.40$3.8353,410 shs$94.53 million02/23/2024$3.82$3.89+1.83%$3.96$3.8143,622 shs$86.32 million02/22/2024$3.80$3.82+0.53%$3.99$3.7540,115 shs$84.77 million02/21/2024$3.76$3.80+1.06%$3.99$3.7179,351 shs$84.32 million02/20/2024$3.94$3.76-4.57%$4.06$3.4590,361 shs$83.45 million02/19/2024$3.94$3.94$4.11$3.7891,500 shs$87.43 million02/16/2024$4.00$3.94-1.50%$4.11$3.7891,510 shs$87.43 million02/15/2024$3.40$4.00+17.65%$4.22$3.34111,780 shs$88.78 million02/14/2024$3.64$3.40-6.59%$3.72$3.37137,179 shs$75.45 million02/13/2024$3.50$3.64+4.00%$3.65$3.19193,128 shs$80.77 million02/12/2024$3.63$3.50-3.58%$3.74$3.44158,917 shs$77.67 million Related Companies: Lifecore Biomedical Stock Chart Trevi Therapeutics Stock Chart Galectin Therapeutics Stock Chart Rigel Pharmaceuticals Stock Chart Omeros Stock Chart Generation Bio Stock Chart Ovid Therapeutics Stock Chart Alimera Sciences Stock Chart Atossa Therapeutics Stock Chart Organigram Stock Chart Receive ACRV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ACRV) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithCollapse of the Petrodollar Colonial MetalsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.